Popular Articles

In Trastuzumab-Resistant Metastatic Breast Cancer, Small Molecule Inhibitor Shows Promise
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

Global Network Formed To Improve Hearing Implant Outcomes
The Cochlear Implant Program at the London Health Sciences Centre (LHSC) working in collaboration with researchers at The University of Western Ontario"s National Centre for Audiology, has joined 16 other world-class centres to form HEARRING - the International Network of Comprehensive Hearing Implant Centers of Excellence. These centres, which are leaders within their specialities, have come together as a globally networked "cluster". This will allow members to set scientific and clinical standards and raise the quality of patient care.
News of the day
DOR BioPharma Receives FDA Orphan Drug Designation For OrBec(R) For The Treatment Of Chronic Gastrointestinal GVHD
DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oral BDP (beclomethasone 17,21-dipropionate, or orBec((R))) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease (cGVHD) in patients who have undergone allogeneic hematopoietic cell transplantation.
Mental Health

Lower Cancer Risk For Obese Women Who Underwent Weight-Loss Surgery

An article published Online First and in the July edition of The Lancet Oncology indicates that weight-loss surgery known as bariatric surgery could be linked to a reduction in cancer risk in obese women, but not in obese men. The risk of developing different types of cancer is linked to obesity and a high body mass index (BMI). In fact, in the US, about 14 percent of cancer deaths in men and 20 percent in women are directly related to being overweight or obese; makeing it the most preventable cause of cancer besides smoking. But it is still unknown if treatment to reduce obesity can lower cancer incidence. A study was designed in 2007 to assess the effect of long-term weight loss on disease and death rates, called The Swedish Obese Subjects (SOS) study. Findings showed that bariatric surgery was linked to reduced overall mortality. The study found that cancer was the most common cause of death, but it was unable to assess death due to specific causes. Lars Sjē¶strē¶m and his team used data from the ongoing SOS study to look into bariatric surgery and whether it is associated with reduced overall occurrence of cancer. The researchers also evaluated the effects of altered body weight and caloric consumption on cancer incidence. The SOS study assessed 2,010 obese patients who underwent weight-loss surgery in comparison with 2,037 obese patients who received standard treatment, which varied between advanced lifestyle advices to no treatment at all. Between 1987 and 2001, patients aged 37 to 60 years were recruited from twenty five surgical departments and four hundred and eighty primary health-care centers across Sweden. They were monitored for an average of 10.9 years and regularly assessed to detect cancer. Results indicated that weight-loss surgery was related to a considerable decrease in cancer occurrence of 42 percent in obese women. This was not the case in obese men. For over a decade, conventional treatment led to an average weight increase of 1.3 kg, while surgery resulted in a sustained average weight reduction of 19.9 kg. For both sexes combined, the number of first-time cancers was lower in the surgery group than in the standard treatment group (117 cases versus 169 cases). This represents 33 percent less probability in the surgery group to develop cancer. In women, the number of first-time cancers was considerably inferior in the surgery group than in the standard treatment group (79 cases versus 130 cases). This represents 42 percent less probability in the women having weight-reduction surgery to develop cancer. On the other hand, surgery had no effect on cancer occurrence in men, with 39 cases in the standard treatment group versus 38 cases in the surgery group. Additional research pointed out there was no correlation between fewer cancer occurrences and weight loss or lower energy intake. As a result, the authors say the favorable effects of weight-loss surgery on cancer could be the result of different processes other than weight-loss or decreased energy intake, and need further examination. They write in conclusion: "In our study, the significant reduction in overall cancer incidence in the female surgery group emanated from a variety of cancer types, indicating a broad effect of bariatric surgery." In an associated note, Dr Andrew G Renehan, of the Department of Surgery, School of Cancer and Imaging Sciences, University of Manchester, UK, remarks: "The cancer-prevention effects of bariatric surgery seem limited to women, an observation reinforcing the importance of studying mechanisms separately by sex. For the SOS cohort, the absence of effect in men might simply reflect small sample numbers. For women, the greatest cancer-prevention effects from weight reduction are likely to be for post-menopausal breast and endometrial cancers, two hormone-sensitive malignancies, the effects of which might manifest within a decade. By contrast, the effects of weight reversal might take much longer to become apparent for other obesity-related cancers, such as colon, rectal, and kidney cancers, which are numerically more common in men." "Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial" Lars Sjē¶strē¶m, Anders Gummesson, C David Sjē¶strē¶m, Kristina Narbro, Markku Peltonen, Hans Wedel, Calle Bengtsson, Claude Bouchard, Bjē¶rn Carlsson, Sven Dahlgren, Peter Jacobson, Kristjan Karason, Jan Karlsson, Bo Larsson, Anna-Karin Lindroos, Hans Lē¶nroth, Ingmar Nē¤slund, Torsten Olbers, Kaj Stenlē¶f, Jarl Torgerson, Lena M S Carlsson, for the Swedish Obese Subjects Study DOI:10.1016/10.1016/S1470-2045 (09)70159-7 The Lancet/oncology Written by Stephanie Brunner (B.A.) Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):